ACSS2 Inhibitor Program
Substance Use Disorders (Opioid, Alcohol, Nicotine, Cocaine) and PTSD
Pre-clinicalActive
Key Facts
Indication
Substance Use Disorders (Opioid, Alcohol, Nicotine, Cocaine) and PTSD
Phase
Pre-clinical
Status
Active
Company
About EpiVario
EpiVario is a private, preclinical-stage biotech pioneering a novel neuroepigenetic platform targeting the enzyme ACSS2 to disrupt maladaptive memories underlying addiction and PTSD. Spun out of the University of Pennsylvania's Epigenetics Institute, the company leverages foundational discoveries by its scientific founders to develop small molecule inhibitors. Recent milestones include key patent issuances, NIH grant funding, and strategic portfolio licensing, positioning it to address significant unmet needs in neuropsychiatry.
View full company profile